Mylan launches trastuzumab biosimilar for treatment of HER2-positive metastatic breas

[News]

Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that its subsidiary, Mylan Pharmaceuticals Private Limited, has launched the world's first trastuzumab biosimilar in India.

More... (http://www.news-medical.net/news/20140203/Mylan-launches-trastuzumab-biosimilar-for-treatment-of-HER2-positive-metastatic-breast-cancer.aspx)